A phase II study of atrasentan (ABT-627) plus pegylated liposomal encapsulated doxorubicin [doxorubicin liposomal] (Doxil) in patients with recurrent ovarian, fallopian tube, or peritoneal serous papillary adenocarcinoma following platinum + taxane therapy.

Trial Profile

A phase II study of atrasentan (ABT-627) plus pegylated liposomal encapsulated doxorubicin [doxorubicin liposomal] (Doxil) in patients with recurrent ovarian, fallopian tube, or peritoneal serous papillary adenocarcinoma following platinum + taxane therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 May 2012

At a glance

  • Drugs Atrasentan (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 May 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.
    • 27 May 2010 Actual end date changed from 1 Sep 2006 to 1 Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top